Texas TECH University Health Sciences Center

Texas Tech University Health Sciences Center, doing business as Ttuhsc, provides clinical physician services, biomedical research, healthcare workforce development, and medical education to federal agencies as a prime recipient and contractor, with no federal contract prime-awardee status on competitive procurements but extensive IDC and task-order work through the Department of Veterans Affairs. A state-controlled institution of higher learning and child entity of the Texas Tech University System, Ttuhsc is headquartered in Lubbock, Texas, operates five health professions schools (Medicine, Pharmacy, Nursing, Health Professions, and Population Public Health), and serves 108 Texas counties across five campuses (Lubbock, Amarillo, Abilene, Midland/Odessa, and Dallas).

Ttuhsc's federal capability portfolio centers on onsite physician services across multiple medical specialties—pharmacy, urology, neurology, and correctional treatment—delivered through indefinite-delivery contracts with the Department of Veterans Affairs; biomedical research spanning neurodegenerative disease, cancer biology, pain management, infectious disease, and translational medicine funded through NIH institutes and other federal research agencies; healthcare workforce training and development in behavioral health, community health worker certification, and physician assistant rural training; and clinical support and litigative consultation to federal agencies. Recent representative work includes a $4.9 million IDC for pharmacy physician services to Veterans Integrated Service Network 17 (VISN 17) extending through September 2030, a $960,960 delivery order for pharmacy physician services to North Texas Veterans Healthcare System, a $694,525 Army Research Development and Engineering Command basic research grant on radiofrequency electromagnetic field effects on the immune system, a $499,831 Health Resources and Services Administration Primary Care Training and Enhancement grant for residency training in street medicine, and a $388,229 National Institute of Allergy and Infectious Diseases grant investigating endogenous retroviruses and myalgic encephalomyelitis/chronic fatigue syndrome.

Customer concentration is heavily weighted toward the Department of Veterans Affairs and the National Institutes of Health. The top five agencies by award count account for 41 percent of recent awards, led by NIH (74 awards), VISN 17 (54 awards, $37.1 million combined potential value), Health Resources and Services Administration (47 awards), the Navy Bureau of Medicine and Surgery (46 awards, $1.6 million), and the National Cancer Institute (29 awards). By potential value, VISN 17 dominates at $37.1 million across 54 awards, followed by the Department of Justice Bureau of Prisons Central Office ($4.5 million, 23 awards), the Navy ($1.6 million, 46 awards), and VISN 22 ($994 thousand, 9 awards). Ttuhsc competes predominantly in full-and-open procurements; no set-aside categories characterize its prime posture.

Ttuhsc holds active single-award indefinite-delivery contracts with the VA for pharmacy physician services ($4.9 million ceiling through September 2030), onsite urology physician services ($959,737.20 ceiling through March 2027), and neurology physician services ($682,484.50 ceiling through July 2035), as well as a Basic Ordering Agreement with the Navy Bureau of Medicine and Surgery (no dollar ceiling, through July 2035). The top parent vehicles by task-order volume include Navy IDC N0014098G2543 (46 task orders, $1.4 million combined potential value), Department of Justice IDC DJBCTS497 (11 task orders, $2 million), and DJBTDAT165 (8 task orders, $578 thousand). Activity has remained relatively stable year over year—20 awards in 2022, rising to 30 in 2023 and 2025, with 26 in 2024 and 11 through mid-2026—though 29 awards with combined potential value of $1.1 million face ultimate completion inside the next twenty-four months and therefore represent recompete exposure.

Ttuhsc acts as prime on 91 percent of recent awards (550 prime contracts, grants, and IDCs) and as sub-recipient or subcontractor on 9 percent (55 sub-awards). SCI-reported invoicing of $593 thousand in FY2023 across 4.3 FTEs on federal service contracts above the $150,000 threshold reflects only a narrow subset of federal services activity; the institutional footprint is far larger. Government-paid hourly rates on SCI-reportable work run at a median of $65.75/hr across physician and clinical labor, with no meaningful sub-engagement on those contracts. Ttuhsc does not appear to leverage subcontractors materially for service delivery; it builds its own workforce. As a sub-recipient on federal grants, Ttuhsc partners with research universities (Cornell University, Vanderbilt University Medical Center, University of Arizona, Texas A&M University System Health Science Center, Augusta University Research Institute, Emory University, and others) on multi-institutional research teams led by external principal investigators, with roles ranging from data analysis and animal model work to biospecimen collection and processing.

Recent federal grant footprint spans health professions education, biomedical research, and infrastructure. Ttuhsc is a recipient on a cooperative agreement from the National Heart Lung and Blood Institute ($12.5 million, extending through February 2027) titled "The Future of Rural Health: Accelerating Biomedical Excellence at TTUHSC," a Health Resources and Services Administration Primary Care Training and Enhancement project grant for physician assistant rural training in behavioral health (CFDA 93.884, $2.019 million, 2024–2029), and multiple NIH R01 and R21 project grants in cancer biology, neurodegeneration, pain mechanisms, and infectious disease. Congressionally directed spending awards include an $8 million HHS healthcare infrastructure construction grant (September 2023, completion 2026) and a telehealth hub project (September 2023, $2.1 million). Ttuhsc also acts as sub-recipient on large cooperative agreements anchored by other research universities, including a Children's Hospital of Philadelphia PO1 on neuroblastoma therapy resistance, a National Cancer Institute cooperative on ALT cancer vulnerabilities (University of Michigan lead), and NIH/NIDCR randomized controlled trials on speech intervention via telepractice for cleft palate (University of Arizona and others, multiple cooperative agreements, 2021 and later).

Ttuhsc receives substantial operational support through training and workforce-development grants. The institution holds active HRSA Bureau of Health Professionals awards for physician assistant education, community health worker training, health center infrastructure support, and telehealth resource-center operations. It participates in NSF education and innovation programs, including I-Corps projects on biofeedback systems, nanoantibiotics, burn injury diagnosis, and hemorrhage-control training devices. The institution's research intensity is confirmed by average NIH funding of $12.5 million annually (FY2020–2022), placing it in the high-research-activity category, and a broad portfolio spanning NIAID, NCI, NINDS, NIA, NIAAA, NIGMS, NHLBI, NIDCR, NSF, Army, and DOE agencies across basic science, translational, and clinical-trial methodologies.